Aim
NTproBNP is a serum biomarker of congestive heart failure (CHF) that is originated from ventricles due to myocardial stretch. Galectin is a novel serum biomarker of myocardial fibrosis and represents the myocardial remodeling. We evaluated the relationship of Galectin 3 and NT-ProBNP and whether galectin 3 could be used in the diagnosis of CHF in patients with signs and symptom.
Material-Method
Totally, 42 patients with signs and symptoms of CHF and 40 asymptomatic subjects as control group were enrolled to the study. Echocardiographic parameters of Left ventricle and atrium, serum levels of NT-proBNP, cTnI, and Galectin 3 were compared among groups. Regression analysis of NT-proBNP and Galectin was performed and predictive role of Galectin 3 for CHF were determined by ROC curve analysis.
Material-Method
Totally, 42 patients with signs and symptoms of CHF and 40 asymptomatic subjects as control group were enrolled to the study. Echocardiographic parameters of Left ventricle and atrium, serum levels of NT-proBNP, cTnI, and Galectin 3 were compared among groups. Regression analysis of NT-proBNP and Galectin was performed and predictive role of Galectin 3 for CHF were determined by ROC curve analysis.
Results
LVIDd/s and LVVolSys/Dias were significantly increased in patients with CHF group. However NT-proBNP (377.65±317.24 vs 528.55±461.64, p=0.124), cTnI (235.40±145.49 vs 276.79±158.74, p=0.323) were not different among groups while Galectin 3 (317.55±90.68 vs 475.21±299.32, p=0.003) significantly elevated in patients with CHF. We observed that Galectin 3 was significantly (R=0.632, R2=0.399, p<0.001) correlated with NT-proBNP. Also we found that Galectin levels ≥358 could diagnose the CHF with sensitivity and specificity of 57% and 83%, respectively (AUC 0.687 CI 0.569-0.806, p=0.003)
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
